No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
www.chugai-pharm.co.jpNo one on the platform currently holds 4519.T.
No tracked institution reports a position in 4519.T as of their last filing.
No one on the platform has traded 4519.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 26.8% | 29.1% | 23.9% | — | — | — |
| Rev. Growth % | 7.5% | 9.8% | ||||
| Profit Margin % | 34.5% | 31.4% | 24.8% | |||
| Free Cash Flow Margin % | 24.9% | 24.7% | 18.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.38T | +10.8% | $307.72 | $297.21–$318.40 | — | 14 |
| 2027 | $1.52T | +10.1% | $354.24 | $307.27–$400.74 | — | 15 |
| 2028 | $1.67T | +9.7% | $403.78 | $345.13–$462.19 | — | 14 |
| 2029 | $1.86T | +11.7% | $467.98 | $439.36–$517.21 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-24 | $75.67 | $69.19 | -8.6% |
| 2026-04-24 | $66.38 | $70.48 | +6.2% |
| 2026-01-29 | $73.97 | $78.03 | +5.5% |
| 2025-10-23 | $77.14 | $78.96 | +2.4% |
| 2025-07-24 | $75.96 | $59.29 | -21.9% |
| 2025-04-24 | $48.76 | $56.54 | +16.0% |
| 2025-01-30 | $56.53 | $54.80 | -3.1% |
| 2024-10-25 | $61.50 |
| $66.55 |
| +8.2% |
| -4.11% |
| $680.7B |
| — |
| 4523.TEisai Co., Ltd. | $4785.00 | +0.38% | $1.35T | — |
| 4528.TOno Pharmaceutical Co., Ltd. | $2330.00 | -1.00% | $1.09T | — |
Source: Financial Modeling Prep · peers by sector/industry